COMBACTE Highlights of 2021
In 2021, COMBACTE had a scientifically rich year.
COMBACTE-CDI ended
Started in November 2017, the project had come a long way and yielded important results. Most importantly, despite a small delay due to the corona pandemic, it achieved what it set out to do more than three years ago: develop a detailed understanding of the epidemiology and clinical impact of CDI across the whole healthcare economy in Europe.
The Launch of ECRAID-Base
ECRAID-Base is the unification of several networks into one central sustainable infrastructure. The networks built by COMBACTE and PREPARE will allow running clinical research faster, easier, and more cost-effective. Pooling our forces, knowledge and expertise will help tackle the most urgent healthcare threats.
At the heart of ECRAID-Base are six perpetual studies. All will mature towards adaptive platform trials, with capability to rapidly respond to public health threats. One such platform is REMAP-CAP which was adapted to include COVID-19 treatment domains within two months after the outbreak.
A New Partner in Aridis Pharmaceuticals
With Aridis as a new official EFPIA partner within COMBACTE-NET, Aridis Pharmaceuticals and COMBACTE-NET continue their research on this monoclonal antibody in the SAATELLITE-2 clinical trial.
“I am delighted to continue the collaboration with COMBACTE to design and conduct the Phase 3 study to evaluate suvratoxumab (AR-320) after the successful collaboration of the Phase 2 SAATELLITE study. It is an excellent opportunity to build on the lessons learned and efficiencies gained up till now”
– Hasan Jafri, Chief Medical Officer and Head of Clinical Development at Aridis Pharmaceuticals
The start of Phase 3 Study MICROCARE
This news was followed by obtaining the authorizations from 7 regulatory authorities in Europe, including France, Germany, Spain and Denmark.
The MICROCARE trial shall enroll 900 patients newly-diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome treated with intensive chemotherapy in approximately 80 centers worldwide.
“We believe that protecting the microbiome of patients with acute myeloid leukemia is a clinically meaningful goal, as patients with disrupted microbiome have more life-threatening complications and a lower survival rate.”
– Fabien Vitry, M.D., Chief Medical Officer of Da Volterra
Science from the COMBACTE Consortium
On April 14th, ANTICIPATE’s results were published in Nature Communications in a back-to-back publication. In the clinical trial was concluded that bacterial composition in the colon can be used to recognize patients at increased risk of infection with the bacterium Clostridium difficile after a course of antibiotics. Read more
On the 22nd of April, The SAATELLITE study announced that the manuscript entitled “Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus Ventilator-Associated Pneumonia (SAATELLITE): a randomized clinical trial” was published in The Lancet Infectious Diseases journal. Read more
A total of 9 scientific articles were published from the different COMBACTE projects. An overview of all publications of 2021 can be found here.
During the COMBACTE General Assembly, the COMBACTE Poster and Presentation Platform was launched, including the most recent study updates across COMBACTE-NET, -MAGNET and -CARE projects. All updates are available as short videos presented by members of the studies or networks. Visit the platform
ECCMID 2021
COMBACTE was represented by a total of 19 abstracts: 6 from COMBACTE-NET, 10 from COMBACTE-MAGNET, 1 from COMBACTE-CARE and 2 from COMBACTE-CDI. Check out an overview of COMBACTE’s abstracts here. Another highlight of this year was the many young scientist of COMBACTE involved in the congress, read more on what they had to say about their research here.
Related updates
“We Take Bigger Steps Together”
COMBACTE's Last General Assembly
COMBACTE Launches Last Magazine
COMBACTE launched its last magazine at ECCMID 2023 in Copenhagen. The magazine focuses on project’s impact, and features articles and interviews with ...